Premium
Meta‐analysis: clinicopathological and prognostic significance of cyclooxygenase‐2 expression on oesophageal squamous cell carinoma
Author(s) -
LI L.,
ZHAO J.,
WU Z.,
WANG G.,
CHEN G.
Publication year - 2009
Publication title -
alimentary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.308
H-Index - 177
eISSN - 1365-2036
pISSN - 0269-2813
DOI - 10.1111/j.1365-2036.2009.04069.x
Subject(s) - medicine , cyclooxygenase , meta analysis , oncology , squamous cell cancer , expression (computer science) , esophageal squamous cell carcinoma , basal cell , pathology , carcinoma , cancer , enzyme , biochemistry , chemistry , computer science , programming language
Summary Background Cyclooxygenase‐2 (COX‐2) is involved in oesophageal carcinogenesis, but the clinical and prognostic significance of COX‐2 expression in oesophageal squamous cell carcinoma (ESCC) remains controversial. Aim To evaluate the clinicopathological and prognostic role of COX‐2 expression in ESCC. Methods Studies assessing clinical or prognostic significance of COX‐2 expression in ESCC published until December 2008 were selected. A meta‐analysis was performed to clarify the impact of COX‐2 expression on clinicopathological parameters or overall survival (OS) in ESCC. Results A total of 19 studies met the inclusion criteria, among which 17 studies were about the clinicopathological significance of COX‐2 expression in ESCC, 12 studies were dealing with prognostic role of COX‐2 expression in ESCC and 10 studies evaluated both of them. Overexpression of COX‐2 was significantly correlated with not only the depth of invasion and TNM stage, with a combined odds ratio (OR) of 0.55 (95%CI: 0.34–0.90, Z = 2.41, P = 0.02) and 0.55 (95%CI: 0.32–0.95, Z = 2.13, P = 0.03) respectively but also the reduced OS with relative risk (RR) 1.42, 95% CI: 1.07–1.90, Z = 2.43, P = 0.02). Conclusions COX‐2 might play an important role in the progress of ESCC, overexpression of COX‐2 correlates with not only the depth of invasion and TNM stage but also the reduced OS. COX‐2 might be a potential therapy target for ESCC and work as a prognostic factor for ESCC patients, yet the clinicopathological and prognostic role of COX‐2 in ESCC still needs further confirmation by well‐designed prospective studies.